AMN Healthcare's Demand Inflection: Nurses Return, Stock Soars

AMN Healthcare's stock has been on a tear—up nearly 93% over the past 90 trading days—and its Q2 2026 report provides the fundamental catalyst. The company beat its own guidance by 6% on revenue and posted a 26% jump in adjusted EBITDA, with management openly describing a demand increase that is broad-based across regions, provider types, and service models. This is a cyclical inflection point, and the tape is leading the fundamentals.

The Demand Inflection

Most striking is the re-acceleration in the core business. “Travel nurse volume showed 6% year-over-year growth and Allied volume grew 7%, both the highest growth rate these businesses have achieved in 4 years.” — Caroline Grace, CEO · 2026-08-06 For context, travel nurse orders turned positive in May and were up about 40% year-over-year by early August, with allied orders growing at mid-teens rates in June and July. Management attributes this to a combination of pent-up patient demand, a slowdown in permanent hiring, and the growing cost competitiveness of contingent labor—now at a historically low premium. As Cary Grace noted: “pre-COVID, you would have seen that premium of contingent to permanent labor be in the mid- to high teens... now back down into the mid- to high single digits.” — Caroline Grace, CEO · 2026-08-06

What makes this more than a blip is the company's improving Fill rates, particularly in vendor-neutral and third-party channels where AMN historically underperformed. The team has been investing in process automation and AI-enabled recruiting, and the payoff is visible: 6% travel nurse volume growth in Q2 (12% above consensus) and 7% allied growth. The momentum has continued into Q3 guidance, which calls for double-digit year-over-year volume growth in both businesses.

The Bumps in the Road

It's not all clean. Roughly $27 million of Q2 revenue and 290 basis points of gross margin came from non-recurring labor disruption billing true-ups and reserve reversals—items management explicitly flagged as not repeating in Q3. Yet even excluding those, core revenue topped guidance by nearly 2%, and EBITDA margin landed at the top of the 6.7%-7.2% guide. The labor disruption business itself remains lumpy—Q2 had $25 million vs. a $10 million assumption—but it's a capability that deepens client relationships during crises.

Strategically, AMN is making small but deliberate moves. The acquisitions of Jaide Health (AI-enabled language interpretation) and ESSENTIAL Brand Leadership Assessment extend its platform into adjacent services. Management's tone on M&A has shifted: “We're in a position now that if the right opportunity comes along, we think it would be accretive, then we can participate more actively than we might have been able to 12 or 24 months ago.” — Brian Scott, CFO · 2026-08-06 With effective net cash at $629 million and leverage at 1.5x, the balance sheet is finally a weapon rather than a constraint.

What's Changed vs. Last Quarter

Six months ago, the story was about stabilization and waiting for orders to return. In “conversations with clients had shifted back to what are the levers that we can use to more sustainably create a high-quality cost-effective workforce” — Caroline Grace, Chief Executive Officer · 2026-05-08—that was the tone in May. Now the order books are growing, and management is openly discussing 2027 growth in international nursing, locum tenens, and leadership search. The prior call even had them projecting a return to year-over-year growth in 2027; this quarter they're front-loading some of that into Q3 guidance.

There are still risks. The RFP process for the large Kaiser contract is competitive, and bill rates remain flat even as volumes climb—management expects a lag effect but acknowledges rate increases are needed to sustain supply. The International Nurse growth is constrained by embassy appointment backlogs, which could temper 2027 expectations. And the margin guidance for Q3 (6.5%-7% EBITDA) is below Q2's 10.9%, consistent with the one-time nature of the labor disruption benefits.

Still, the market is voting with its feet. The 90-day chart shows a +92.8% move, with the recent peak at $36.60 and only a 5.8% drawdown—a clear breakout. As CEO Cary Grace put it:

We're seeing a broad-based demand... that you would typically expect to see a positive tailwind to seeing demand increase throughout the next couple of quarters. And we want to see 3, 4-plus consecutive quarters of that.